close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soligenix, Inc. - Common Stock (NQ:SNGX)

1.580 -0.020 (-1.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Soligenix, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advances HyBryte(TM) as Potential First-Line CTCL Treatment with Promising FLASH Results
Via Investor Brand Network
Researchers Develop Nanoparticles That Could Combat Scarring, Inflammation in ARLD
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Updates U.S. Medical Advisory Board to Advance Phase 3 Development of HyBryte for CTCL
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Closes Multimillion-Dollar Public Offering to Fund Pipeline Through 2026
Via Investor Brand Network
How You Can Support Your Loved One Undergoing Cancer Treatment
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Reports Positive Safety Review from DMC in Ongoing Phase 3 FLASH2 Study of HyBryte for CTCL
Via Investor Brand Network
Rapid Spread of ‘Nightmare Bacteria’ Triggers Alarm
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Closes $7.5 Million Public Offering to Extend Cash Runway Through 2026
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board to Advance HyBryte Phase 3 Study
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances Psoriasis Trial with Encouraging Patient Results, Market Potential
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Strengthens Position in CTCL Treatment with HyBryte(TM) FLASH Results
Via Investor Brand Network
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Appoints Tomas J. Philipson, PhD as Strategic Advisor
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Leveraging Positive Clinical Data to Shape Pivotal SGX942 Trial
Via Investor Brand Network
UCLA Researchers Receive $2M Grant to Study MRI-Guided Cancer Radiation Therapy
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation
Via Investor Brand Network
Senior NIH Officials Allege Retaliation as Motive for Their Ouster
Via Investor Brand Network
Topics Whistleblower
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Data Demonstrating Two-Year Stability of ThermoVax Ebolavirus Vaccines
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Treatment with FDA Orphan Designation
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
Study Explains Why Blood Clotting is Common in IBD Patients
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline
Via Investor Brand Network
Synergy Corp. (NASDAQ: SNYR) 1,600+ Nationwide Store Rollout – PPCB, SNGX, BTAI, HIT + Other Disruptive Stocks Moving Now!
Via AB Newswire
Topics Artificial Intelligence
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Awarded FDA Orphan Drug Designation for Dusquetide in Behçet’s Disease
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
Via Investor Brand Network
Study Finds That Low BSA Psoriasis Could Have a High Disease Burden
Via Investor Brand Network
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Q2 2025 Results Highlight Progress in Late-Stage Rare Disease Pipeline
Via Investor Brand Network
InvestorNewsBreaks – Alliance Global Partners Maintains Buy Rating, Increases Price Target as Soligenix Inc. (NASDAQ: SNGX) Advances Proprietary Clinical Programs
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Featured in NNW Editorial on Rare Disease Innovation
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Proprietary Platform Aims to Meet Growing Need for Effective CTCL Therapy
From Soligenix, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today